An overview of the use of natural compounds to reduce drug resistance in conventional cancer therapy: The role of polysaccharide krestin (psk)

2^nd International Conference and Exhibition on Traditional & Alternative Medicine

August 25-26, 2014 DoubleTree by Hilton Beijing, China

Manuela Malaguti-Boyle

Accepted Abstracts: Altern Integ Med

Abstract :

Clinical Pears: Appreciation of PSK, a semipurified polysaccharide obtained from the mushroom Coriolus versicolour used extensively in clinical cancer treatment, particularly in Japan. As a whole, several human clinical research studies strongly suggest that PSK inhibit cancer progression and improve postoperative survival in humans due to a combination of immune stimulation and inhibition of immuno suppressive cytokines. Background: Cancer cells are better able to adapt to stress than normal cells. In cancer treatment, this adaptation results in tumour cells that develop cancer resistance to chemotherapy drugs. This event is usually the primary obstacle to successful treatment. Finding themselves in a state of high alert, cancer cells have the ability to express resistance not only to drugs they have been exposed to, but to any other noxious agent. Multi-drug resistance is a protection mechanism that can lead to failure of the conventional cancer treatment. Research shows that natural compounds can reverse drug resistance by inhibition of P-glycoprotein, inhibition of glutathione S-transferase drug detoxification system and inhibition of heat-shock proteins. There is ample evidence suggesting that natural compounds can produce cytotoxic effects in cancer cell through a number of mechanisms and that, when they are combined with chemotherapy drugs, these effects are often additive or synergistic. Methods: A review of randomized controlled trails of the mechanisms by which cancer cells, exposed to chemotherapy, have the ability to devise strategies for resistance and survival. EBSCO, MedLine, and PubMed articles from 1992 to 2012 to were researched to retrieve suitable information. Five double blind placebo controlled clinical human and animal studies were reviewed. Results: All the control studies conducted in large multi-centre trials, confirmed improvement in patient survival on a dose of 3 grams of PSK per day orally unless noted. Key findings are as follow: 1. Two hundred sixty-two postoperative stomach cancer patients were randomized to receive chemotherapy or chemotherapy and PSK. The addition of PSK increased the five-year disease-free rate (from 59% to 71%) and the five year survival rate (from 60% to 73%). 2. Four hundred and sixty-two patients with curatively resected colon cancer were randomized to receive chemotherapy or chemotherapy plus PSK. The latter combination increased the eight-year disease free rate (from about 7.8% to 28 %) and the ten year survival rate (from 19% to 36%). 3. Two hundred and seventy-eight patients with stage II aT2N1 estrogen-dependent breast cancer were randomized to receive chemotherapy or chemotherapy. The administration of PSK increased the five year survival rate (from 81% to 96%). Disease-free survival also increased. 4. Thirty-eight patients with nasopharyinx cancer who were treated with radiotherapy, with or without chemotherapy, were randomised to receive PSK or no PSK. The addition of PSK increased survival rate (from 15 to 35 months). The PSK dose was 1 gram per day orally. 5. Thirty-eight patients with nasopharyinx cancer who were treated with radiotherapy, with or without chemotherapy, were randomised to receive PSK or no PSK. The addition of PSK increased survival rate (from 15 to 35 months). The PSK dose was 1 gram per day orally. Conclusion: These results demonstrate that Polysaccharide-K (PSK) has potent anti-tumour effects.